Teva Pharmaceutical Industries LimitedTEVA
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NYSE · Israel · tevapharm.com
Teva Pharmaceutical Industries is transforming into an innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years it has innovated in neuroscience and immunology while providing complex generic medicines, biosimilars and pharmacy brands worldwide. The NYSE line is an ADR; the shares are also listed on the Tel Aviv Stock Exchange.
Key ratios
Operating cash flow growth
36.6%TTM
2025
32.2%2024
-8.9%2023
-14.0%
FCF / Sales
6.7%2025
2024
4.5%2023
5.3%
Net margin
8.2%2025
2024
-9.9%2023
-3.5%
ROA
6.2%2025
2024
5.1%2023
4.6%
ROE
20.8%2025
2024
-28.3%2023
-7.4%
Revenue growth
4.1%TTM
2025
4.3%2024
4.4%2023
6.2%
Recent news
Teva's Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO, AJOVY and UZEDY; Delivers Substantial Gross Margin Expansion
Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
UEG Week: Teva and Sanofi's Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn's Disease
Teva to Host R&D Day on Wednesday, November 11 in New York City
Journal of Child Neurology Publishes Review Highlighting Dopamine's Role in Tourette Syndrome and Ecopipam's Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
TAPI (Technology & API Services) Names Serge Rogasik CEO to Lead Next Chapter of Growth and Competitiveness
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy
Track TEVA in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer